SlideShare a Scribd company logo
Blood Transfusion
in Obstetrics
Prof. Aboubakr Elnashar
Benha university Hospital
Egypt
elnashar53@hotmail.com
ABOUBAR ELNASHAR
CONTENTS
 INTRODUCTION
1. RISKS
2. SPECIFIC TO PREGNANCY
3. REDUCING RISK
4. GENERAL PRINCIPLES
ABOUBAR ELNASHAR
5. INDICATIONS
1. Anaemia
2. OBS Hge
1. Causes
2. Estimation
3. Management
4. Controversies
5. How much & when to
stop
6. Blood components
 SUMMARY
INTRODUCTION
Obstetric hge:
major cause of maternal mortality
in the UK: 3rd leading
In Egypt: 1st leading
Postpartum hge
25% of all pregnancy-related deaths.
ABOUBAR ELNASHAR
Blood transfusion
 one of 8 essential components to reduce maternal
mortality rates.
As ‘too little, too late’.
Women at high risk of losing 1000 ml:
should deliver in a setting where
blood transfusion
intensive care facilities are available.
Life-saving procedure
ABOUBAR ELNASHAR
 In developing countries
 Availability of blood transfusion depends on
 Infrastructure
 Economics
 Social and religious taboos
 Practices
 : transfusion practices vary from those in
the developed countries
ABOUBAR ELNASHAR
1. RISKS OF BLOOD TRANSFUSION
1. Transfusion-transmitted infections
2. Immunological sequelae:
red cell alloimmunisation.
3. The major risk: ‘incorrect blood component’.
Strict adherence to:
 correct sampling
 cross-match
Administration procedures:
paramount importance, even in an emergency.
ABOUBAR ELNASHAR
2. PROBLEMS SPECIFIC TO THE PREGNANCY
1. Physiological changes in pregnancy
a. Haemodilution
Increase in
red cell mass (20-30%)
plasma volume (50%):
patient stay haemodynamically stable with
the normal blood loss during delivery.
b. Decrease in platelet levels:
gestational thrombocytopenia.
ABOUBAR ELNASHAR
c. Hypercoagulable state
Increase in
coagulation factors:
fibrinogen and factors VII, VIII, and IX
supervening over the increase in the natural
anticoagulants:
Protein A, Protein C, and Antithrombin III.
Fibrinolytic system decreases in activity.
Plasminogen is increased, but its activity is dampened by a
corresponding increase in plasminogen inhibitor type II.
Hypercoagulable state
limit blood loss
can tip the mother into:
DIC and
Pulmonary embolism.
ABOUBAR ELNASHAR
2. Difficulty in assessment of blood loss by
Vital signs:
{increased maternal plasma volume}.
 Haemodilution and high cardiac output: large
amount of blood loss in a pregnant female
before the hypotension and fall in Hgb/ Hct
Visual assessment
{large amounts of blood lost may be concealed in
the uterine cavity}.
ABOUBAR ELNASHAR
3. Associated comorbid conditions
 PET
 Thrombocytopenia
 HELLP syndrome
 can bring about catastrophic hge.
ABOUBAR ELNASHAR
4. Risk to foetus
 While managing acute haemorrhagic emergencies,
the foetus has to be kept in mind, to prevent
 Infections
 Haemolytic Disease of the Foetus and Newborn
(HDFN) in the current and future pregnancies.
ABOUBAR ELNASHAR
3. REDUCING RISK OF BLOOD TRANSFUSION
1. Optimization of Hb in ANC
Screening
 at booking
 at 28 w.
 at 20–24 w in multiple pregnancies
Diagnosis
 1st T. Hb: ≤11.0 g/l
 2nd &3rd T. Hb: ≤ 10.5 g/l
 Postpartum Hb: ≤ 10.0 g/l
ABOUBAR ELNASHAR
Treatment
Inform patient
How to improve dietary iron intake
Factors affecting absorption of dietary iron
Oral iron:
1st TT line.
:if no demonstrable rise in Hb at 2 ws
Check compliance
Further TT
Parenteral iron
indicated when
 oral iron is not tolerated
 absorbed
 patient compliance is in doubt
 if the woman is approaching term and there is insufficient time
for oral supplementation to be effective.
ABOUBAR ELNASHAR
2. Active management of the third stage of labour
 To minimise blood loss.
 Involve
 use of uterotonics
 early clamping of the cord
 controlled cord traction
3. Women at high risk of hge
should be advised to deliver in hospital.
ABOUBAR ELNASHAR
4. GENERAL PRINCIPLES OF BLOOD
TRANSFUSION
1. Consent for blood transfusion
obtained where possible
In an emergency:
information on blood transfusion should be
provided retrospectively.
Document in patient case notes
Reason for transfusion
Consent
ABOUBAR ELNASHAR
2. All women should have
blood group and
antibody status
checked at
Booking
28 w.
Group and screen samples used for provision of blood in pregnancy should be
less than 3 days old.
Transfusion or pregnancy may stimulate the production of unexpected
antibodies against red cell antigens through either a primary or secondary
immune response. To ensure that the specimen used for compatibility testing is
representative of a patient’s current immune status, serological studies should
be performed using blood collected no more than 3 days in advance of the
actual transfusion when the patient has been transfused or pregnant within the
preceding 3 months.
ABOUBAR ELNASHAR
In a woman at high risk of emergency transfusion:
Placenta praevia, and with no clinically significant alloantibodies
 group and screen samples
 should be sent once a week
 {exclude or identify any new antibody formation}
 keep blood available if necessary.
 Close contact with the hospital transfusion
laboratory is essential.
ABOUBAR ELNASHAR
3. Blood product specification in pregnancy&puerperium
ABO-, rhesus D- (RhD-) and K- (Kell-)
compatible red cell units should be transfused.
If clinically significant red cell antibodies are present:
blood negative for the relevant antigen should be
cross-matched before transfusion; close contact with the
transfusion laboratory is essential to avoid delay in transfusion in life-
threatening hge.
CMV seronegative red cell
Platelet components:
should be provided for elective transfusions during
pregnancy.
ABOUBAR ELNASHAR
5. INDICATIONS OF BLOOD TRANSFUSION IN
OBSTETRICS
I. Anaemia of pregnancy and Haemoglobinopathies
II. Obstetric hge
III. Surgeries where significant blood loss is expected.
ABOUBAR ELNASHAR
I. BLOOD TRANSFUSION FOR ANAEMIA
 Antepartum anaemia
 responsible for 15% of maternal mortality.
 Early correction:
 avoids the need for transfusion
 reduces maternal mortality.
 The decision for transfusion
 should not be made on the basis of Hgb alone
 Healthy&clinically stable women do not require
blood transfusion even with Hb of <7 g/dl.
ABOUBAR ELNASHAR
Indications: Cochrane SR, 2007
1. Hb <6 g/dl
there are <4 ws for delivery
2. Hb is <7 g/dl
 in labour or
 in immediate postpartum period, if there is
 previous history of bleeding or
 patient is prone for bleeding due to some
medical condition.
3. Hb is 7 g/dl
 continued bleeding or
 at risk of further significant hge or
 presenting with severe symptoms that need
immediate correction (cardiac decompensation).
ABOUBAR ELNASHAR
4. Sickle disease and thalassaemia
 severe situations
{prophylactic transfusion:
 increases in costs
 number of hospitalizations
 risk of alloimmunisation}.
ABOUBAR ELNASHAR
II. BLOOD TRANSFUSION FOR OBSTETRIC
HAEMORRHAGE
 The leading cause of maternal mortality
 13% in developed countries
 33% in Africa.
[WHO, 2006]
 may occur before or after delivery
 >80% of cases occur postpartum
[McLintock , James, 2011]
ABOUBAR ELNASHAR
1. Causes Of Obstetric Haemorrhage
 Early pregnancy
 Abortions
 Ectopic pregnancy
 Later pregnancy
 Antepartum haemorrhage
 Placenta praevia, placental abruption
 bleeding from vaginal or cervical lesions
 Primary postpartum haemorrhage
 Tone (uterine atony)
 Tissue (retained products)
 Trauma (cervical and genital tract damage during delivery)
 Thrombin (coagulation disorder)
 Secondary postpartum haemorrhage
 Uterine atony
 retained products
 genital tract trauma,
 uterine inversion ABOUBAR ELNASHAR
2. Estimation Of Blood Loss
1. Visual assessment:
 Inaccurate
 clinicians can underestimate blood loss by 50%.
 PPH
 >500 ml after VD and
 >1000 ml after CS, do not adequately reflect the
clinical response of the patient.
 Massive hge
 1000-1500 ml
 50% blood volume loss within 3-h or
 rate of loss of 150 ml/min.
ABOUBAR ELNASHAR
2. HCT
 Immediate Hct will not reflect actual blood loss.
 Even blood loss of 1000 ml will reflect a fall
in Hct of only 3% in the 1st h.
3. Urine output
 sensitive to changes in blood volume
 can give an early indication of changes in renal
perfusion and hence perfusion of other organs.
4. Pulse Oximetry
 an imperfect tool in the haemodynamically
unstable patient.
ABOUBAR ELNASHAR
 More accurate methods:
1. Weighing packs:
 Hospital keeps scales in delivery rooms to weigh lap sponges &
other materials to estimate blood loss.
 1kg soaked swabs: 1000ml
2. Comparing visual estimation of blood loss with the
use of a collector bag
soda can hold about 350 cc of blood
concluded that the latter did not significantly reduce the risk of severe
PPH.
ABOUBAR ELNASHAR
3. Written guidelines
 Maximum capacity of Swab
 Small (10x10cm): 60ml
 Medium (30x30 cm): 140ml
 Large (45x45 cm): 350ml
 Floor spill
 50 cm diameter: 500ml
 75 cm diameter: 1000ml
 100 cm diameter: 1500ml
 Vaginal PPH
 Limited to bed only unlikely to exceed 1000ml
 Spilling from bed to floor likely to exceed
1000ml
ABOUBAR ELNASHAR
4. Pictorial guidelines
ABOUBAR ELNASHAR
3. Management Of Obstetric Haemorrhage
Multidisciplinary approach to massive blood loss yields
the best results.
ACOG:
The CMQCC protocol
Step-by-step checklist format
Based on the staging of obstetric hge
RCOG
Therapeutic and monitoring guidelines for minor and
major postpartum hge
While there are some individual variations, the broad
outlines remain the same. ABOUBAR ELNASHAR
The 4 mainstay of management of hge:
1. Rapid resuscitation with crystalloids:
 restore and maintain the circulating blood
volume
 prevent tissue and organ hypo-perfusion.
2. Blood transfusion in acute hge:
 maintain tissue oxygenation
 reversal or prevention of coagulopathy using
appropriate blood components.
ABOUBAR ELNASHAR
3. Prevention& treatment of
 hypothermia,
 acidosis
 hypocalcaemia:
optimal function of transfused coagulation factors.
4. Simultaneously, the cause of bleeding should be
 Identified
 controlled, by
 medical means
 surgery or
 invasive radiography.
ABOUBAR ELNASHAR
Major PPH >1000 ml or ShockMinor PPH <1000 ml
&Compensated
Airway, Breathing& Circulation
O2 by mask at 10–15 L/M
14-gauge cannula x2
Blood component rapidly
Packed RBC: Fresh frozen plasma:
Platelets= 6:4:1
Until blood is available: IV up to 3.5 L
crystalloid lactated Ringer (± one L of it
is colloid)
Keep patient& infusions warm
IV access one 14-
gauge cannula
Crystalloid infusion:
1-1.5 L lactated Ringer
ABOUBAR ELNASHAR
4. Controversies For Transfusion In Obstetrics
1. Colloids or Crystalloids:
 have no advantage over Crystalloids
 high cost
(The SAFE trial and the CRISTAL trial)
Crystalloids
rapidly equilibrate with the extracellular fluid
 only 20% remains in circulation after 1st h.
The accepted average ratio of Colloid: Crystalloid is
1:1.5.
ABOUBAR ELNASHAR
Crystalloid:
NS
D5NS can be given
Ringer
Hartmann
Ringer=lactated Ringer
Nacl: 6.5 g,
Kcl:0.42 g,
Ca cl: 0.25 g,
1 mol of Na bicarbonate
is dissolved in 1 liter of distilled water
Colloids:
Human albumin,
Hydroxyethylstarch (HES)
Dextran
Mannitol
Haemaccel
ABOUBAR ELNASHAR
Hartmann solution= compound
sodium lactate
NaCl
KCl
CaCl dihydrate
Na lactate
2. Whole blood or blood component?
superior to PRBCs or combined transfusions in
preventing acute tubular necrosis and other
complications.
replaces many coagulation factors
its plasma expands blood volume.
 exposing the patient to fewer donors.
The availability of fresh warm blood in developing countries
could provide an alternative to more expensive and infra
structure-dependent blood components.
ABOUBAR ELNASHAR
3. To cross-match or not to cross-match?
The chances of a clinically significant red cell
antibody being missed in a patient with a negative
antibody screen (false negative) are
1-4/10,000.
Given that the chance of adverse consequences is
small, in cases of acute massive hge, it appears
reasonable to transfuse blood without
type-and-screened red blood cells.
[Rege et al, 2014]
ABOUBAR ELNASHAR
5. Blood Transfusion: How Much& When To Stop?
 The decision for blood transfusion
 Hb≤6.0 g/dl
 almost always required
 Hb≥10.0 g/dl
 rarely required
 Hb is normal but acute hge
 Required
 Single Hb/ hct
 ±misleading
 ±:delay initiating red cell transfusion
 Serial measurements helpful
ABOUBAR ELNASHAR
 Goals of management of massive blood loss:
 Most protocols recommend maintaining a target
 Hct of 21-24%.
 Restrictive transfusions and liberal transfusions were of equivalent
value in critically ill patients while relatively stable patients undergoing
liberal transfusions had a higher 30-day mortality.
 [Hébert et al, 2012]
Hb ≥8 g/dl
Platelet 50x 109/L
PT ≤1.5 times normal
APPT ≤1.5 times normal
Fibrinogen 2g/L
ABOUBAR ELNASHAR
The risk of dilutional coagulopathy
 needs to be borne in mind when multiple units of
PRBCs and crystalloids/colloids are used.
<10 units of PRBCs rarely need component
replacement
The lowest mortality occurs in the patients where
ratio of plasma and PRBCs is 1:1.
Recommend ratio of PRBC, fresh frozen plasma and
Platelet of 6: 4:1 in cases of massive hge.
ABOUBAR ELNASHAR
6. Management Of Obstetric Haemorrhage With Blood
Components
There should be a clear local protocol on how to
manage major obstetric hge.
The protocol should be updated annually and practised
in ‘skills drills’ to inform and train relevant personnel.
ABOUBAR ELNASHAR
1. Clinicians should familiarise themselves with
mechanical strategies that can be employed to
reduce postpartum blood loss.
rubbing up the fundus
bimanual uterine compression
emptying the bladder to stimulate uterine
contraction
ABOUBAR ELNASHAR
2. Blood components used for obstetric hge
Red cell transfusion
The decision to provide blood transfusion should
be made on clinical and haematological grounds.
 almost always required when Hb ≤60 g/l
 rarely required when the Hb≥100 g/l.
Patients with acute hge can have normal Hb: cl
evaluation of the patient is extremely important.
ABOUBAR ELNASHAR
In an extreme situation and when the blood group is
unknown:
group O RhD-negative red cells should be given
(although they may be incompatible for patients with
irregular antibodies).
Staff working in obstetric units should be aware of the location of the satellite blood
fridge (where available) and should ensure that access is possible for blood collection.
ABOUBAR ELNASHAR
FFP
Dose:
12–15 ml/kg for/6 units of red cells during major
obstetric hge.
Subsequent FFP transfusion should be guided by
the results of clotting tests, aiming to maintain PT
and APTT ratios at less than 1.5 x normal.
During bleeding episodes:
Regular full blood counts
coagulation screens (PT, APTT and fibrinogen)
are performed
ABOUBAR ELNASHAR
Cryoprecipitate
 Dose:
 two 5-unit pools should be administered early in
major obstetric hge.
 Subsequent transfusion should be guided by
fibrinogen results
 aiming to keep levels above 1.5 g/l.
ABOUBAR ELNASHAR
Platelets
Aim:
maintain the platelet count above 50 x 109/l in the
acutely bleeding patient.
A platelet transfusion trigger of 75 x 109/l is
recommended to provide a margin of safety.
The platelets should ideally be group compatible.
RhD-negative women should also receive RhD-
negative platelets.
ABOUBAR ELNASHAR
SUMMARY
Blood transfusion is an essential component of
obstetric care and at times lifesaving.
Inappropriate transfusions during pregnancy and the
postpartum period expose the mother to the risk of
HDFN.
In the situation of obstetric hge early resuscitation is
done with crystalloids with oxygenation while
simultaneously taking all steps to control bleeding and
reduce the transfusion requirement.
A preplanned, multidisciplinary protocol yields the best
results in the management.
ABOUBAR ELNASHAR
The decision to perform a blood transfusion should be
made on both clinical and haematological grounds.
The majority of protocols recommended that Hct be
maintained minimally at 21-24%; however, in actively
bleeding patient, target Hct should be 30%.
To avoid dilutional coagulopathy,replacement with
coagulation factors and platelets may be necessary.
Whole blood may be preferred in acute massive hge,
especially where blood components are not available.
In an extreme situation and when the blood group is
unknown, O RhD negative red cells should be given.
ABOUBAR ELNASHAR
ABOUBAR ELNASHAR
You can get this lecture from:
1.My scientific page on Face book:
Aboubakr Elnashar Lectures.
https://www.facebook.com/groups/2277
44884091351/
2.Slide share web site
3.elnashar53@hotmail.com
4.My clinic: Elthwara St. Mansura

More Related Content

What's hot

Thrombocytopenia during pregnancy
Thrombocytopenia during pregnancyThrombocytopenia during pregnancy
Thrombocytopenia during pregnancy
Aboubakr Elnashar
 
Thalassemia in pregnancy
Thalassemia in pregnancyThalassemia in pregnancy
Thalassemia in pregnancy
Jibran Mohsin
 
FIRST-TRIMESTER SCREENING & PREVENTION OF PET FIGO, 2019
FIRST-TRIMESTER SCREENING & PREVENTION OF PET FIGO, 2019FIRST-TRIMESTER SCREENING & PREVENTION OF PET FIGO, 2019
FIRST-TRIMESTER SCREENING & PREVENTION OF PET FIGO, 2019
Aboubakr Elnashar
 
Thrombocytopenia during pregnancy
Thrombocytopenia during pregnancyThrombocytopenia during pregnancy
Thrombocytopenia during pregnancy
muhammad al hennawy
 
THROMBOPROPHYLAXIS DURING PREGNANCY, LABOUR AND AFTER DELIVERY
THROMBOPROPHYLAXIS  DURING PREGNANCY, LABOUR  AND AFTER DELIVERYTHROMBOPROPHYLAXIS  DURING PREGNANCY, LABOUR  AND AFTER DELIVERY
THROMBOPROPHYLAXIS DURING PREGNANCY, LABOUR AND AFTER DELIVERY
Aboubakr Elnashar
 
Non immune hydrops latest
Non immune hydrops latestNon immune hydrops latest
Non immune hydrops latest
Anita Srinivasan
 
Thrombophilia and ٍٍRecurrent Pregnancy Loss
Thrombophilia and ٍٍRecurrent Pregnancy LossThrombophilia and ٍٍRecurrent Pregnancy Loss
Thrombophilia and ٍٍRecurrent Pregnancy Loss
Marwan Alhalabi
 
Rh isoimmunization
Rh isoimmunizationRh isoimmunization
Rh isoimmunization
imanswati
 
PPH DRILL SAFOG
PPH DRILL SAFOGPPH DRILL SAFOG
PPH DRILL SAFOG
NARENDRA MALHOTRA
 
Blood transfusion reactions and complications
Blood transfusion reactions and complicationsBlood transfusion reactions and complications
Blood transfusion reactions and complications
SCGH ED CME
 
Venous Thromboembolism in Obstetrics
Venous Thromboembolism in ObstetricsVenous Thromboembolism in Obstetrics
Venous Thromboembolism in Obstetrics
limgengyan
 
Overview of IUGR FGR
Overview of IUGR FGROverview of IUGR FGR
Overview of IUGR FGR
Dr.Laxmi Agrawal Shrikhande
 
Critical Care in Pregnancy
Critical Care in PregnancyCritical Care in Pregnancy
Critical Care in Pregnancy
Omar Khaled
 
Rh isoimmunization
Rh isoimmunization Rh isoimmunization
Rh isoimmunization
Anu Manivannan
 
OHSS - management osama warda 
OHSS - management  osama warda OHSS - management  osama warda 
OHSS - management osama warda 
Osama Warda
 
Rh Rhesus Isoimmunization
Rh Rhesus Isoimmunization Rh Rhesus Isoimmunization
Rh Rhesus Isoimmunization
Chukwuma Onyeije, MD, FACOG
 
Rh isoimmunization
Rh isoimmunizationRh isoimmunization
Rh isoimmunization
kaleemusmani52
 
OBSTETRIC PPH DRILL
OBSTETRIC PPH DRILLOBSTETRIC PPH DRILL
OBSTETRIC PPH DRILL
NARENDRA MALHOTRA
 

What's hot (20)

Thrombocytopenia during pregnancy
Thrombocytopenia during pregnancyThrombocytopenia during pregnancy
Thrombocytopenia during pregnancy
 
Thalassemia in pregnancy
Thalassemia in pregnancyThalassemia in pregnancy
Thalassemia in pregnancy
 
Anemia in pregnancy
Anemia in pregnancyAnemia in pregnancy
Anemia in pregnancy
 
FIRST-TRIMESTER SCREENING & PREVENTION OF PET FIGO, 2019
FIRST-TRIMESTER SCREENING & PREVENTION OF PET FIGO, 2019FIRST-TRIMESTER SCREENING & PREVENTION OF PET FIGO, 2019
FIRST-TRIMESTER SCREENING & PREVENTION OF PET FIGO, 2019
 
Thrombocytopenia during pregnancy
Thrombocytopenia during pregnancyThrombocytopenia during pregnancy
Thrombocytopenia during pregnancy
 
THROMBOPROPHYLAXIS DURING PREGNANCY, LABOUR AND AFTER DELIVERY
THROMBOPROPHYLAXIS  DURING PREGNANCY, LABOUR  AND AFTER DELIVERYTHROMBOPROPHYLAXIS  DURING PREGNANCY, LABOUR  AND AFTER DELIVERY
THROMBOPROPHYLAXIS DURING PREGNANCY, LABOUR AND AFTER DELIVERY
 
Non immune hydrops latest
Non immune hydrops latestNon immune hydrops latest
Non immune hydrops latest
 
Anti Coagulation In Pregnancy
Anti Coagulation In PregnancyAnti Coagulation In Pregnancy
Anti Coagulation In Pregnancy
 
Thrombophilia and ٍٍRecurrent Pregnancy Loss
Thrombophilia and ٍٍRecurrent Pregnancy LossThrombophilia and ٍٍRecurrent Pregnancy Loss
Thrombophilia and ٍٍRecurrent Pregnancy Loss
 
Rh isoimmunization
Rh isoimmunizationRh isoimmunization
Rh isoimmunization
 
PPH DRILL SAFOG
PPH DRILL SAFOGPPH DRILL SAFOG
PPH DRILL SAFOG
 
Blood transfusion reactions and complications
Blood transfusion reactions and complicationsBlood transfusion reactions and complications
Blood transfusion reactions and complications
 
Venous Thromboembolism in Obstetrics
Venous Thromboembolism in ObstetricsVenous Thromboembolism in Obstetrics
Venous Thromboembolism in Obstetrics
 
Overview of IUGR FGR
Overview of IUGR FGROverview of IUGR FGR
Overview of IUGR FGR
 
Critical Care in Pregnancy
Critical Care in PregnancyCritical Care in Pregnancy
Critical Care in Pregnancy
 
Rh isoimmunization
Rh isoimmunization Rh isoimmunization
Rh isoimmunization
 
OHSS - management osama warda 
OHSS - management  osama warda OHSS - management  osama warda 
OHSS - management osama warda 
 
Rh Rhesus Isoimmunization
Rh Rhesus Isoimmunization Rh Rhesus Isoimmunization
Rh Rhesus Isoimmunization
 
Rh isoimmunization
Rh isoimmunizationRh isoimmunization
Rh isoimmunization
 
OBSTETRIC PPH DRILL
OBSTETRIC PPH DRILLOBSTETRIC PPH DRILL
OBSTETRIC PPH DRILL
 

Similar to Blood transfusion in ostetrics2019

Blood Transfusion in Obstetrics Green-top Guideline 2015
Blood Transfusion in Obstetrics Green-top Guideline 2015Blood Transfusion in Obstetrics Green-top Guideline 2015
Blood Transfusion in Obstetrics Green-top Guideline 2015
Aboubakr Elnashar
 
TREATMENT GUIDELINES OF SOCIETY OF MATERNAL AND FETAL MEDICINE
TREATMENT GUIDELINES OF SOCIETY OF MATERNAL AND FETAL MEDICINETREATMENT GUIDELINES OF SOCIETY OF MATERNAL AND FETAL MEDICINE
TREATMENT GUIDELINES OF SOCIETY OF MATERNAL AND FETAL MEDICINE
Aboubakr Elnashar
 
A fatal case of complicated HELLP Syndrome and Antepartum Eclamptic Fit with ...
A fatal case of complicated HELLP Syndrome and Antepartum Eclamptic Fit with ...A fatal case of complicated HELLP Syndrome and Antepartum Eclamptic Fit with ...
A fatal case of complicated HELLP Syndrome and Antepartum Eclamptic Fit with ...
Apollo Hospitals
 
Monitoring ART cycle Aboubakr Elnashar
Monitoring ART cycle Aboubakr ElnasharMonitoring ART cycle Aboubakr Elnashar
Monitoring ART cycle Aboubakr Elnashar
Aboubakr Elnashar
 
thrombocytopenia in pregnancy.pptx
thrombocytopenia in pregnancy.pptxthrombocytopenia in pregnancy.pptx
thrombocytopenia in pregnancy.pptx
biswajitbhuyan14
 
ta.pptx
ta.pptxta.pptx
THE SICKLE CELL DISEASE IN PREGNANCY.pptx
THE SICKLE CELL DISEASE IN PREGNANCY.pptxTHE SICKLE CELL DISEASE IN PREGNANCY.pptx
THE SICKLE CELL DISEASE IN PREGNANCY.pptx
Dr Issah J.K
 
Recent advances in management of PET
Recent advances in management of PET Recent advances in management of PET
Recent advances in management of PET
Aboubakr Elnashar
 
Thromboembolic disease In obstetrics and Gynaecology
Thromboembolic disease  In obstetrics and  GynaecologyThromboembolic disease  In obstetrics and  Gynaecology
Thromboembolic disease In obstetrics and Gynaecology
Aboubakr Elnashar
 
dc dutta
dc duttadc dutta
Post partum haemorrhage
Post partum haemorrhage Post partum haemorrhage
Post partum haemorrhage
Dr Zharifhussein
 
pph-150512151237-lva1-app6892.pptx
pph-150512151237-lva1-app6892.pptxpph-150512151237-lva1-app6892.pptx
pph-150512151237-lva1-app6892.pptx
dimasfujiansyah1
 
ANAESTHESIA FOR ANTEPARTUM HAEMORHHAGE
ANAESTHESIA FOR ANTEPARTUM HAEMORHHAGEANAESTHESIA FOR ANTEPARTUM HAEMORHHAGE
ANAESTHESIA FOR ANTEPARTUM HAEMORHHAGE
shashikantsharma109
 
Hemolytic disease of the newborn. Diagnosis & Treatment
Hemolytic disease of the newborn. Diagnosis & TreatmentHemolytic disease of the newborn. Diagnosis & Treatment
Hemolytic disease of the newborn. Diagnosis & Treatment
Eneutron
 
Medical management of Post Partum Haemorrhage
Medical management of Post Partum HaemorrhageMedical management of Post Partum Haemorrhage
Medical management of Post Partum Haemorrhage
Nandini Jahagirdar Joshi
 
seminar on anemia in newborn
seminar on anemia in newbornseminar on anemia in newborn
seminar on anemia in newborn
Dr. Habibur Rahim
 
Abnormal uterine bleeding
Abnormal  uterine bleedingAbnormal  uterine bleeding
Abnormal uterine bleeding
Aboubakr Elnashar
 
Anaesthetic management of obstetric emergencies
Anaesthetic management of  obstetric emergenciesAnaesthetic management of  obstetric emergencies
Anaesthetic management of obstetric emergencies
Vidhi Gajjar
 
Management of Thromboembolic Disease in Pregnancy and Puerperium
Management of Thromboembolic Disease  in Pregnancy and  PuerperiumManagement of Thromboembolic Disease  in Pregnancy and  Puerperium
Management of Thromboembolic Disease in Pregnancy and Puerperium
Aboubakr Elnashar
 

Similar to Blood transfusion in ostetrics2019 (20)

Blood Transfusion in Obstetrics Green-top Guideline 2015
Blood Transfusion in Obstetrics Green-top Guideline 2015Blood Transfusion in Obstetrics Green-top Guideline 2015
Blood Transfusion in Obstetrics Green-top Guideline 2015
 
TREATMENT GUIDELINES OF SOCIETY OF MATERNAL AND FETAL MEDICINE
TREATMENT GUIDELINES OF SOCIETY OF MATERNAL AND FETAL MEDICINETREATMENT GUIDELINES OF SOCIETY OF MATERNAL AND FETAL MEDICINE
TREATMENT GUIDELINES OF SOCIETY OF MATERNAL AND FETAL MEDICINE
 
A fatal case of complicated HELLP Syndrome and Antepartum Eclamptic Fit with ...
A fatal case of complicated HELLP Syndrome and Antepartum Eclamptic Fit with ...A fatal case of complicated HELLP Syndrome and Antepartum Eclamptic Fit with ...
A fatal case of complicated HELLP Syndrome and Antepartum Eclamptic Fit with ...
 
Monitoring ART cycle Aboubakr Elnashar
Monitoring ART cycle Aboubakr ElnasharMonitoring ART cycle Aboubakr Elnashar
Monitoring ART cycle Aboubakr Elnashar
 
thrombocytopenia in pregnancy.pptx
thrombocytopenia in pregnancy.pptxthrombocytopenia in pregnancy.pptx
thrombocytopenia in pregnancy.pptx
 
ta.pptx
ta.pptxta.pptx
ta.pptx
 
THE SICKLE CELL DISEASE IN PREGNANCY.pptx
THE SICKLE CELL DISEASE IN PREGNANCY.pptxTHE SICKLE CELL DISEASE IN PREGNANCY.pptx
THE SICKLE CELL DISEASE IN PREGNANCY.pptx
 
Recent advances in management of PET
Recent advances in management of PET Recent advances in management of PET
Recent advances in management of PET
 
Thromboembolic disease In obstetrics and Gynaecology
Thromboembolic disease  In obstetrics and  GynaecologyThromboembolic disease  In obstetrics and  Gynaecology
Thromboembolic disease In obstetrics and Gynaecology
 
Pph
PphPph
Pph
 
dc dutta
dc duttadc dutta
dc dutta
 
Post partum haemorrhage
Post partum haemorrhage Post partum haemorrhage
Post partum haemorrhage
 
pph-150512151237-lva1-app6892.pptx
pph-150512151237-lva1-app6892.pptxpph-150512151237-lva1-app6892.pptx
pph-150512151237-lva1-app6892.pptx
 
ANAESTHESIA FOR ANTEPARTUM HAEMORHHAGE
ANAESTHESIA FOR ANTEPARTUM HAEMORHHAGEANAESTHESIA FOR ANTEPARTUM HAEMORHHAGE
ANAESTHESIA FOR ANTEPARTUM HAEMORHHAGE
 
Hemolytic disease of the newborn. Diagnosis & Treatment
Hemolytic disease of the newborn. Diagnosis & TreatmentHemolytic disease of the newborn. Diagnosis & Treatment
Hemolytic disease of the newborn. Diagnosis & Treatment
 
Medical management of Post Partum Haemorrhage
Medical management of Post Partum HaemorrhageMedical management of Post Partum Haemorrhage
Medical management of Post Partum Haemorrhage
 
seminar on anemia in newborn
seminar on anemia in newbornseminar on anemia in newborn
seminar on anemia in newborn
 
Abnormal uterine bleeding
Abnormal  uterine bleedingAbnormal  uterine bleeding
Abnormal uterine bleeding
 
Anaesthetic management of obstetric emergencies
Anaesthetic management of  obstetric emergenciesAnaesthetic management of  obstetric emergencies
Anaesthetic management of obstetric emergencies
 
Management of Thromboembolic Disease in Pregnancy and Puerperium
Management of Thromboembolic Disease  in Pregnancy and  PuerperiumManagement of Thromboembolic Disease  in Pregnancy and  Puerperium
Management of Thromboembolic Disease in Pregnancy and Puerperium
 

More from Aboubakr Elnashar

WHAT IS NEW IN ESHRE 2022 AND FIGO 2022 FOR GENERAL GYNAECOLOGIST
WHAT IS NEW IN ESHRE 2022 AND FIGO 2022 FOR GENERAL GYNAECOLOGISTWHAT IS NEW IN ESHRE 2022 AND FIGO 2022 FOR GENERAL GYNAECOLOGIST
WHAT IS NEW IN ESHRE 2022 AND FIGO 2022 FOR GENERAL GYNAECOLOGIST
Aboubakr Elnashar
 
hepatitis B.pdf
hepatitis B.pdfhepatitis B.pdf
hepatitis B.pdf
Aboubakr Elnashar
 
hepatitis c2022.pdf
hepatitis c2022.pdfhepatitis c2022.pdf
hepatitis c2022.pdf
Aboubakr Elnashar
 
Adenomyosis associated infertility
Adenomyosis associated  infertilityAdenomyosis associated  infertility
Adenomyosis associated infertility
Aboubakr Elnashar
 
Endometriosis associated infertility: ESHRE2022
Endometriosis associated infertility: ESHRE2022Endometriosis associated infertility: ESHRE2022
Endometriosis associated infertility: ESHRE2022
Aboubakr Elnashar
 
Adenxal mass guidelines2020
Adenxal mass guidelines2020Adenxal mass guidelines2020
Adenxal mass guidelines2020
Aboubakr Elnashar
 
Aesthetic gynecology controversy
Aesthetic gynecology controversyAesthetic gynecology controversy
Aesthetic gynecology controversy
Aboubakr Elnashar
 
Hormonal assay in clinical gyn
Hormonal assay in clinical gynHormonal assay in clinical gyn
Hormonal assay in clinical gyn
Aboubakr Elnashar
 
FIRST TRIMESTER ANC OF IVF
FIRST TRIMESTER ANC OF IVFFIRST TRIMESTER ANC OF IVF
FIRST TRIMESTER ANC OF IVF
Aboubakr Elnashar
 
Unnecessary investigations in reproductive medicine
Unnecessary investigations in reproductive medicineUnnecessary investigations in reproductive medicine
Unnecessary investigations in reproductive medicine
Aboubakr Elnashar
 
Infertility prevention
Infertility prevention Infertility prevention
Infertility prevention
Aboubakr Elnashar
 
Individualisation of controlled ovarian stimulation
Individualisation of controlled ovarian stimulationIndividualisation of controlled ovarian stimulation
Individualisation of controlled ovarian stimulation
Aboubakr Elnashar
 
Female infertility
Female infertility Female infertility
Female infertility
Aboubakr Elnashar
 
Maternal near miss
Maternal near missMaternal near miss
Maternal near miss
Aboubakr Elnashar
 
THE MANAGEMENT OF SEVERE PET/ECLAMPSIA
THE MANAGEMENT OF SEVERE PET/ECLAMPSIA THE MANAGEMENT OF SEVERE PET/ECLAMPSIA
THE MANAGEMENT OF SEVERE PET/ECLAMPSIA
Aboubakr Elnashar
 
cesarean birth: procedural aspects: NICE2021
cesarean birth: procedural aspects: NICE2021  cesarean birth: procedural aspects: NICE2021
cesarean birth: procedural aspects: NICE2021
Aboubakr Elnashar
 
CAESAREAN SCAR DEFECT
CAESAREAN SCAR DEFECT  CAESAREAN SCAR DEFECT
CAESAREAN SCAR DEFECT
Aboubakr Elnashar
 
Management of pregnancy of unknown location
Management of pregnancy of unknown locationManagement of pregnancy of unknown location
Management of pregnancy of unknown location
Aboubakr Elnashar
 
Aerobic Vaginitis
Aerobic Vaginitis Aerobic Vaginitis
Aerobic Vaginitis
Aboubakr Elnashar
 
COVID 19 infection and pregnancy RCOG2021
COVID 19 infection and pregnancy RCOG2021COVID 19 infection and pregnancy RCOG2021
COVID 19 infection and pregnancy RCOG2021
Aboubakr Elnashar
 

More from Aboubakr Elnashar (20)

WHAT IS NEW IN ESHRE 2022 AND FIGO 2022 FOR GENERAL GYNAECOLOGIST
WHAT IS NEW IN ESHRE 2022 AND FIGO 2022 FOR GENERAL GYNAECOLOGISTWHAT IS NEW IN ESHRE 2022 AND FIGO 2022 FOR GENERAL GYNAECOLOGIST
WHAT IS NEW IN ESHRE 2022 AND FIGO 2022 FOR GENERAL GYNAECOLOGIST
 
hepatitis B.pdf
hepatitis B.pdfhepatitis B.pdf
hepatitis B.pdf
 
hepatitis c2022.pdf
hepatitis c2022.pdfhepatitis c2022.pdf
hepatitis c2022.pdf
 
Adenomyosis associated infertility
Adenomyosis associated  infertilityAdenomyosis associated  infertility
Adenomyosis associated infertility
 
Endometriosis associated infertility: ESHRE2022
Endometriosis associated infertility: ESHRE2022Endometriosis associated infertility: ESHRE2022
Endometriosis associated infertility: ESHRE2022
 
Adenxal mass guidelines2020
Adenxal mass guidelines2020Adenxal mass guidelines2020
Adenxal mass guidelines2020
 
Aesthetic gynecology controversy
Aesthetic gynecology controversyAesthetic gynecology controversy
Aesthetic gynecology controversy
 
Hormonal assay in clinical gyn
Hormonal assay in clinical gynHormonal assay in clinical gyn
Hormonal assay in clinical gyn
 
FIRST TRIMESTER ANC OF IVF
FIRST TRIMESTER ANC OF IVFFIRST TRIMESTER ANC OF IVF
FIRST TRIMESTER ANC OF IVF
 
Unnecessary investigations in reproductive medicine
Unnecessary investigations in reproductive medicineUnnecessary investigations in reproductive medicine
Unnecessary investigations in reproductive medicine
 
Infertility prevention
Infertility prevention Infertility prevention
Infertility prevention
 
Individualisation of controlled ovarian stimulation
Individualisation of controlled ovarian stimulationIndividualisation of controlled ovarian stimulation
Individualisation of controlled ovarian stimulation
 
Female infertility
Female infertility Female infertility
Female infertility
 
Maternal near miss
Maternal near missMaternal near miss
Maternal near miss
 
THE MANAGEMENT OF SEVERE PET/ECLAMPSIA
THE MANAGEMENT OF SEVERE PET/ECLAMPSIA THE MANAGEMENT OF SEVERE PET/ECLAMPSIA
THE MANAGEMENT OF SEVERE PET/ECLAMPSIA
 
cesarean birth: procedural aspects: NICE2021
cesarean birth: procedural aspects: NICE2021  cesarean birth: procedural aspects: NICE2021
cesarean birth: procedural aspects: NICE2021
 
CAESAREAN SCAR DEFECT
CAESAREAN SCAR DEFECT  CAESAREAN SCAR DEFECT
CAESAREAN SCAR DEFECT
 
Management of pregnancy of unknown location
Management of pregnancy of unknown locationManagement of pregnancy of unknown location
Management of pregnancy of unknown location
 
Aerobic Vaginitis
Aerobic Vaginitis Aerobic Vaginitis
Aerobic Vaginitis
 
COVID 19 infection and pregnancy RCOG2021
COVID 19 infection and pregnancy RCOG2021COVID 19 infection and pregnancy RCOG2021
COVID 19 infection and pregnancy RCOG2021
 

Recently uploaded

Flu Vaccine Alert in Bangalore Karnataka
Flu Vaccine Alert in Bangalore KarnatakaFlu Vaccine Alert in Bangalore Karnataka
Flu Vaccine Alert in Bangalore Karnataka
addon Scans
 
Prix Galien International 2024 Forum Program
Prix Galien International 2024 Forum ProgramPrix Galien International 2024 Forum Program
Prix Galien International 2024 Forum Program
Levi Shapiro
 
Hemodialysis: Chapter 3, Dialysis Water Unit - Dr.Gawad
Hemodialysis: Chapter 3, Dialysis Water Unit - Dr.GawadHemodialysis: Chapter 3, Dialysis Water Unit - Dr.Gawad
Hemodialysis: Chapter 3, Dialysis Water Unit - Dr.Gawad
NephroTube - Dr.Gawad
 
For Better Surat #ℂall #Girl Service ❤85270-49040❤ Surat #ℂall #Girls
For Better Surat #ℂall #Girl Service ❤85270-49040❤ Surat #ℂall #GirlsFor Better Surat #ℂall #Girl Service ❤85270-49040❤ Surat #ℂall #Girls
For Better Surat #ℂall #Girl Service ❤85270-49040❤ Surat #ℂall #Girls
Savita Shen $i11
 
basicmodesofventilation2022-220313203758.pdf
basicmodesofventilation2022-220313203758.pdfbasicmodesofventilation2022-220313203758.pdf
basicmodesofventilation2022-220313203758.pdf
aljamhori teaching hospital
 
KDIGO 2024 guidelines for diabetologists
KDIGO 2024 guidelines for diabetologistsKDIGO 2024 guidelines for diabetologists
KDIGO 2024 guidelines for diabetologists
د.محمود نجيب
 
Ophthalmology Clinical Tests for OSCE exam
Ophthalmology Clinical Tests for OSCE examOphthalmology Clinical Tests for OSCE exam
Ophthalmology Clinical Tests for OSCE exam
KafrELShiekh University
 
Knee anatomy and clinical tests 2024.pdf
Knee anatomy and clinical tests 2024.pdfKnee anatomy and clinical tests 2024.pdf
Knee anatomy and clinical tests 2024.pdf
vimalpl1234
 
Ocular injury ppt Upendra pal optometrist upums saifai etawah
Ocular injury  ppt  Upendra pal  optometrist upums saifai etawahOcular injury  ppt  Upendra pal  optometrist upums saifai etawah
Ocular injury ppt Upendra pal optometrist upums saifai etawah
pal078100
 
Triangles of Neck and Clinical Correlation by Dr. RIG.pptx
Triangles of Neck and Clinical Correlation by Dr. RIG.pptxTriangles of Neck and Clinical Correlation by Dr. RIG.pptx
Triangles of Neck and Clinical Correlation by Dr. RIG.pptx
Dr. Rabia Inam Gandapore
 
263778731218 Abortion Clinic /Pills In Harare ,
263778731218 Abortion Clinic /Pills In Harare ,263778731218 Abortion Clinic /Pills In Harare ,
263778731218 Abortion Clinic /Pills In Harare ,
sisternakatoto
 
NVBDCP.pptx Nation vector borne disease control program
NVBDCP.pptx Nation vector borne disease control programNVBDCP.pptx Nation vector borne disease control program
NVBDCP.pptx Nation vector borne disease control program
Sapna Thakur
 
New Drug Discovery and Development .....
New Drug Discovery and Development .....New Drug Discovery and Development .....
New Drug Discovery and Development .....
NEHA GUPTA
 
micro teaching on communication m.sc nursing.pdf
micro teaching on communication m.sc nursing.pdfmicro teaching on communication m.sc nursing.pdf
micro teaching on communication m.sc nursing.pdf
Anurag Sharma
 
24 Upakrama.pptx class ppt useful in all
24 Upakrama.pptx class ppt useful in all24 Upakrama.pptx class ppt useful in all
24 Upakrama.pptx class ppt useful in all
DrSathishMS1
 
ARTIFICIAL INTELLIGENCE IN HEALTHCARE.pdf
ARTIFICIAL INTELLIGENCE IN  HEALTHCARE.pdfARTIFICIAL INTELLIGENCE IN  HEALTHCARE.pdf
ARTIFICIAL INTELLIGENCE IN HEALTHCARE.pdf
Anujkumaranit
 
Report Back from SGO 2024: What’s the Latest in Cervical Cancer?
Report Back from SGO 2024: What’s the Latest in Cervical Cancer?Report Back from SGO 2024: What’s the Latest in Cervical Cancer?
Report Back from SGO 2024: What’s the Latest in Cervical Cancer?
bkling
 
Phone Us ❤85270-49040❤ #ℂall #gIRLS In Surat By Surat @ℂall @Girls Hotel With...
Phone Us ❤85270-49040❤ #ℂall #gIRLS In Surat By Surat @ℂall @Girls Hotel With...Phone Us ❤85270-49040❤ #ℂall #gIRLS In Surat By Surat @ℂall @Girls Hotel With...
Phone Us ❤85270-49040❤ #ℂall #gIRLS In Surat By Surat @ℂall @Girls Hotel With...
Savita Shen $i11
 
Pulmonary Thromboembolism - etilogy, types, medical- Surgical and nursing man...
Pulmonary Thromboembolism - etilogy, types, medical- Surgical and nursing man...Pulmonary Thromboembolism - etilogy, types, medical- Surgical and nursing man...
Pulmonary Thromboembolism - etilogy, types, medical- Surgical and nursing man...
VarunMahajani
 
Maxilla, Mandible & Hyoid Bone & Clinical Correlations by Dr. RIG.pptx
Maxilla, Mandible & Hyoid Bone & Clinical Correlations by Dr. RIG.pptxMaxilla, Mandible & Hyoid Bone & Clinical Correlations by Dr. RIG.pptx
Maxilla, Mandible & Hyoid Bone & Clinical Correlations by Dr. RIG.pptx
Dr. Rabia Inam Gandapore
 

Recently uploaded (20)

Flu Vaccine Alert in Bangalore Karnataka
Flu Vaccine Alert in Bangalore KarnatakaFlu Vaccine Alert in Bangalore Karnataka
Flu Vaccine Alert in Bangalore Karnataka
 
Prix Galien International 2024 Forum Program
Prix Galien International 2024 Forum ProgramPrix Galien International 2024 Forum Program
Prix Galien International 2024 Forum Program
 
Hemodialysis: Chapter 3, Dialysis Water Unit - Dr.Gawad
Hemodialysis: Chapter 3, Dialysis Water Unit - Dr.GawadHemodialysis: Chapter 3, Dialysis Water Unit - Dr.Gawad
Hemodialysis: Chapter 3, Dialysis Water Unit - Dr.Gawad
 
For Better Surat #ℂall #Girl Service ❤85270-49040❤ Surat #ℂall #Girls
For Better Surat #ℂall #Girl Service ❤85270-49040❤ Surat #ℂall #GirlsFor Better Surat #ℂall #Girl Service ❤85270-49040❤ Surat #ℂall #Girls
For Better Surat #ℂall #Girl Service ❤85270-49040❤ Surat #ℂall #Girls
 
basicmodesofventilation2022-220313203758.pdf
basicmodesofventilation2022-220313203758.pdfbasicmodesofventilation2022-220313203758.pdf
basicmodesofventilation2022-220313203758.pdf
 
KDIGO 2024 guidelines for diabetologists
KDIGO 2024 guidelines for diabetologistsKDIGO 2024 guidelines for diabetologists
KDIGO 2024 guidelines for diabetologists
 
Ophthalmology Clinical Tests for OSCE exam
Ophthalmology Clinical Tests for OSCE examOphthalmology Clinical Tests for OSCE exam
Ophthalmology Clinical Tests for OSCE exam
 
Knee anatomy and clinical tests 2024.pdf
Knee anatomy and clinical tests 2024.pdfKnee anatomy and clinical tests 2024.pdf
Knee anatomy and clinical tests 2024.pdf
 
Ocular injury ppt Upendra pal optometrist upums saifai etawah
Ocular injury  ppt  Upendra pal  optometrist upums saifai etawahOcular injury  ppt  Upendra pal  optometrist upums saifai etawah
Ocular injury ppt Upendra pal optometrist upums saifai etawah
 
Triangles of Neck and Clinical Correlation by Dr. RIG.pptx
Triangles of Neck and Clinical Correlation by Dr. RIG.pptxTriangles of Neck and Clinical Correlation by Dr. RIG.pptx
Triangles of Neck and Clinical Correlation by Dr. RIG.pptx
 
263778731218 Abortion Clinic /Pills In Harare ,
263778731218 Abortion Clinic /Pills In Harare ,263778731218 Abortion Clinic /Pills In Harare ,
263778731218 Abortion Clinic /Pills In Harare ,
 
NVBDCP.pptx Nation vector borne disease control program
NVBDCP.pptx Nation vector borne disease control programNVBDCP.pptx Nation vector borne disease control program
NVBDCP.pptx Nation vector borne disease control program
 
New Drug Discovery and Development .....
New Drug Discovery and Development .....New Drug Discovery and Development .....
New Drug Discovery and Development .....
 
micro teaching on communication m.sc nursing.pdf
micro teaching on communication m.sc nursing.pdfmicro teaching on communication m.sc nursing.pdf
micro teaching on communication m.sc nursing.pdf
 
24 Upakrama.pptx class ppt useful in all
24 Upakrama.pptx class ppt useful in all24 Upakrama.pptx class ppt useful in all
24 Upakrama.pptx class ppt useful in all
 
ARTIFICIAL INTELLIGENCE IN HEALTHCARE.pdf
ARTIFICIAL INTELLIGENCE IN  HEALTHCARE.pdfARTIFICIAL INTELLIGENCE IN  HEALTHCARE.pdf
ARTIFICIAL INTELLIGENCE IN HEALTHCARE.pdf
 
Report Back from SGO 2024: What’s the Latest in Cervical Cancer?
Report Back from SGO 2024: What’s the Latest in Cervical Cancer?Report Back from SGO 2024: What’s the Latest in Cervical Cancer?
Report Back from SGO 2024: What’s the Latest in Cervical Cancer?
 
Phone Us ❤85270-49040❤ #ℂall #gIRLS In Surat By Surat @ℂall @Girls Hotel With...
Phone Us ❤85270-49040❤ #ℂall #gIRLS In Surat By Surat @ℂall @Girls Hotel With...Phone Us ❤85270-49040❤ #ℂall #gIRLS In Surat By Surat @ℂall @Girls Hotel With...
Phone Us ❤85270-49040❤ #ℂall #gIRLS In Surat By Surat @ℂall @Girls Hotel With...
 
Pulmonary Thromboembolism - etilogy, types, medical- Surgical and nursing man...
Pulmonary Thromboembolism - etilogy, types, medical- Surgical and nursing man...Pulmonary Thromboembolism - etilogy, types, medical- Surgical and nursing man...
Pulmonary Thromboembolism - etilogy, types, medical- Surgical and nursing man...
 
Maxilla, Mandible & Hyoid Bone & Clinical Correlations by Dr. RIG.pptx
Maxilla, Mandible & Hyoid Bone & Clinical Correlations by Dr. RIG.pptxMaxilla, Mandible & Hyoid Bone & Clinical Correlations by Dr. RIG.pptx
Maxilla, Mandible & Hyoid Bone & Clinical Correlations by Dr. RIG.pptx
 

Blood transfusion in ostetrics2019

  • 1. Blood Transfusion in Obstetrics Prof. Aboubakr Elnashar Benha university Hospital Egypt elnashar53@hotmail.com ABOUBAR ELNASHAR
  • 2. CONTENTS  INTRODUCTION 1. RISKS 2. SPECIFIC TO PREGNANCY 3. REDUCING RISK 4. GENERAL PRINCIPLES ABOUBAR ELNASHAR 5. INDICATIONS 1. Anaemia 2. OBS Hge 1. Causes 2. Estimation 3. Management 4. Controversies 5. How much & when to stop 6. Blood components  SUMMARY
  • 3. INTRODUCTION Obstetric hge: major cause of maternal mortality in the UK: 3rd leading In Egypt: 1st leading Postpartum hge 25% of all pregnancy-related deaths. ABOUBAR ELNASHAR
  • 4. Blood transfusion  one of 8 essential components to reduce maternal mortality rates. As ‘too little, too late’. Women at high risk of losing 1000 ml: should deliver in a setting where blood transfusion intensive care facilities are available. Life-saving procedure ABOUBAR ELNASHAR
  • 5.  In developing countries  Availability of blood transfusion depends on  Infrastructure  Economics  Social and religious taboos  Practices  : transfusion practices vary from those in the developed countries ABOUBAR ELNASHAR
  • 6. 1. RISKS OF BLOOD TRANSFUSION 1. Transfusion-transmitted infections 2. Immunological sequelae: red cell alloimmunisation. 3. The major risk: ‘incorrect blood component’. Strict adherence to:  correct sampling  cross-match Administration procedures: paramount importance, even in an emergency. ABOUBAR ELNASHAR
  • 7. 2. PROBLEMS SPECIFIC TO THE PREGNANCY 1. Physiological changes in pregnancy a. Haemodilution Increase in red cell mass (20-30%) plasma volume (50%): patient stay haemodynamically stable with the normal blood loss during delivery. b. Decrease in platelet levels: gestational thrombocytopenia. ABOUBAR ELNASHAR
  • 8. c. Hypercoagulable state Increase in coagulation factors: fibrinogen and factors VII, VIII, and IX supervening over the increase in the natural anticoagulants: Protein A, Protein C, and Antithrombin III. Fibrinolytic system decreases in activity. Plasminogen is increased, but its activity is dampened by a corresponding increase in plasminogen inhibitor type II. Hypercoagulable state limit blood loss can tip the mother into: DIC and Pulmonary embolism. ABOUBAR ELNASHAR
  • 9. 2. Difficulty in assessment of blood loss by Vital signs: {increased maternal plasma volume}.  Haemodilution and high cardiac output: large amount of blood loss in a pregnant female before the hypotension and fall in Hgb/ Hct Visual assessment {large amounts of blood lost may be concealed in the uterine cavity}. ABOUBAR ELNASHAR
  • 10. 3. Associated comorbid conditions  PET  Thrombocytopenia  HELLP syndrome  can bring about catastrophic hge. ABOUBAR ELNASHAR
  • 11. 4. Risk to foetus  While managing acute haemorrhagic emergencies, the foetus has to be kept in mind, to prevent  Infections  Haemolytic Disease of the Foetus and Newborn (HDFN) in the current and future pregnancies. ABOUBAR ELNASHAR
  • 12. 3. REDUCING RISK OF BLOOD TRANSFUSION 1. Optimization of Hb in ANC Screening  at booking  at 28 w.  at 20–24 w in multiple pregnancies Diagnosis  1st T. Hb: ≤11.0 g/l  2nd &3rd T. Hb: ≤ 10.5 g/l  Postpartum Hb: ≤ 10.0 g/l ABOUBAR ELNASHAR
  • 13. Treatment Inform patient How to improve dietary iron intake Factors affecting absorption of dietary iron Oral iron: 1st TT line. :if no demonstrable rise in Hb at 2 ws Check compliance Further TT Parenteral iron indicated when  oral iron is not tolerated  absorbed  patient compliance is in doubt  if the woman is approaching term and there is insufficient time for oral supplementation to be effective. ABOUBAR ELNASHAR
  • 14. 2. Active management of the third stage of labour  To minimise blood loss.  Involve  use of uterotonics  early clamping of the cord  controlled cord traction 3. Women at high risk of hge should be advised to deliver in hospital. ABOUBAR ELNASHAR
  • 15. 4. GENERAL PRINCIPLES OF BLOOD TRANSFUSION 1. Consent for blood transfusion obtained where possible In an emergency: information on blood transfusion should be provided retrospectively. Document in patient case notes Reason for transfusion Consent ABOUBAR ELNASHAR
  • 16. 2. All women should have blood group and antibody status checked at Booking 28 w. Group and screen samples used for provision of blood in pregnancy should be less than 3 days old. Transfusion or pregnancy may stimulate the production of unexpected antibodies against red cell antigens through either a primary or secondary immune response. To ensure that the specimen used for compatibility testing is representative of a patient’s current immune status, serological studies should be performed using blood collected no more than 3 days in advance of the actual transfusion when the patient has been transfused or pregnant within the preceding 3 months. ABOUBAR ELNASHAR
  • 17. In a woman at high risk of emergency transfusion: Placenta praevia, and with no clinically significant alloantibodies  group and screen samples  should be sent once a week  {exclude or identify any new antibody formation}  keep blood available if necessary.  Close contact with the hospital transfusion laboratory is essential. ABOUBAR ELNASHAR
  • 18. 3. Blood product specification in pregnancy&puerperium ABO-, rhesus D- (RhD-) and K- (Kell-) compatible red cell units should be transfused. If clinically significant red cell antibodies are present: blood negative for the relevant antigen should be cross-matched before transfusion; close contact with the transfusion laboratory is essential to avoid delay in transfusion in life- threatening hge. CMV seronegative red cell Platelet components: should be provided for elective transfusions during pregnancy. ABOUBAR ELNASHAR
  • 19. 5. INDICATIONS OF BLOOD TRANSFUSION IN OBSTETRICS I. Anaemia of pregnancy and Haemoglobinopathies II. Obstetric hge III. Surgeries where significant blood loss is expected. ABOUBAR ELNASHAR
  • 20. I. BLOOD TRANSFUSION FOR ANAEMIA  Antepartum anaemia  responsible for 15% of maternal mortality.  Early correction:  avoids the need for transfusion  reduces maternal mortality.  The decision for transfusion  should not be made on the basis of Hgb alone  Healthy&clinically stable women do not require blood transfusion even with Hb of <7 g/dl. ABOUBAR ELNASHAR
  • 21. Indications: Cochrane SR, 2007 1. Hb <6 g/dl there are <4 ws for delivery 2. Hb is <7 g/dl  in labour or  in immediate postpartum period, if there is  previous history of bleeding or  patient is prone for bleeding due to some medical condition. 3. Hb is 7 g/dl  continued bleeding or  at risk of further significant hge or  presenting with severe symptoms that need immediate correction (cardiac decompensation). ABOUBAR ELNASHAR
  • 22. 4. Sickle disease and thalassaemia  severe situations {prophylactic transfusion:  increases in costs  number of hospitalizations  risk of alloimmunisation}. ABOUBAR ELNASHAR
  • 23. II. BLOOD TRANSFUSION FOR OBSTETRIC HAEMORRHAGE  The leading cause of maternal mortality  13% in developed countries  33% in Africa. [WHO, 2006]  may occur before or after delivery  >80% of cases occur postpartum [McLintock , James, 2011] ABOUBAR ELNASHAR
  • 24. 1. Causes Of Obstetric Haemorrhage  Early pregnancy  Abortions  Ectopic pregnancy  Later pregnancy  Antepartum haemorrhage  Placenta praevia, placental abruption  bleeding from vaginal or cervical lesions  Primary postpartum haemorrhage  Tone (uterine atony)  Tissue (retained products)  Trauma (cervical and genital tract damage during delivery)  Thrombin (coagulation disorder)  Secondary postpartum haemorrhage  Uterine atony  retained products  genital tract trauma,  uterine inversion ABOUBAR ELNASHAR
  • 25. 2. Estimation Of Blood Loss 1. Visual assessment:  Inaccurate  clinicians can underestimate blood loss by 50%.  PPH  >500 ml after VD and  >1000 ml after CS, do not adequately reflect the clinical response of the patient.  Massive hge  1000-1500 ml  50% blood volume loss within 3-h or  rate of loss of 150 ml/min. ABOUBAR ELNASHAR
  • 26. 2. HCT  Immediate Hct will not reflect actual blood loss.  Even blood loss of 1000 ml will reflect a fall in Hct of only 3% in the 1st h. 3. Urine output  sensitive to changes in blood volume  can give an early indication of changes in renal perfusion and hence perfusion of other organs. 4. Pulse Oximetry  an imperfect tool in the haemodynamically unstable patient. ABOUBAR ELNASHAR
  • 27.  More accurate methods: 1. Weighing packs:  Hospital keeps scales in delivery rooms to weigh lap sponges & other materials to estimate blood loss.  1kg soaked swabs: 1000ml 2. Comparing visual estimation of blood loss with the use of a collector bag soda can hold about 350 cc of blood concluded that the latter did not significantly reduce the risk of severe PPH. ABOUBAR ELNASHAR
  • 28. 3. Written guidelines  Maximum capacity of Swab  Small (10x10cm): 60ml  Medium (30x30 cm): 140ml  Large (45x45 cm): 350ml  Floor spill  50 cm diameter: 500ml  75 cm diameter: 1000ml  100 cm diameter: 1500ml  Vaginal PPH  Limited to bed only unlikely to exceed 1000ml  Spilling from bed to floor likely to exceed 1000ml ABOUBAR ELNASHAR
  • 30. 3. Management Of Obstetric Haemorrhage Multidisciplinary approach to massive blood loss yields the best results. ACOG: The CMQCC protocol Step-by-step checklist format Based on the staging of obstetric hge RCOG Therapeutic and monitoring guidelines for minor and major postpartum hge While there are some individual variations, the broad outlines remain the same. ABOUBAR ELNASHAR
  • 31. The 4 mainstay of management of hge: 1. Rapid resuscitation with crystalloids:  restore and maintain the circulating blood volume  prevent tissue and organ hypo-perfusion. 2. Blood transfusion in acute hge:  maintain tissue oxygenation  reversal or prevention of coagulopathy using appropriate blood components. ABOUBAR ELNASHAR
  • 32. 3. Prevention& treatment of  hypothermia,  acidosis  hypocalcaemia: optimal function of transfused coagulation factors. 4. Simultaneously, the cause of bleeding should be  Identified  controlled, by  medical means  surgery or  invasive radiography. ABOUBAR ELNASHAR
  • 33. Major PPH >1000 ml or ShockMinor PPH <1000 ml &Compensated Airway, Breathing& Circulation O2 by mask at 10–15 L/M 14-gauge cannula x2 Blood component rapidly Packed RBC: Fresh frozen plasma: Platelets= 6:4:1 Until blood is available: IV up to 3.5 L crystalloid lactated Ringer (± one L of it is colloid) Keep patient& infusions warm IV access one 14- gauge cannula Crystalloid infusion: 1-1.5 L lactated Ringer ABOUBAR ELNASHAR
  • 34. 4. Controversies For Transfusion In Obstetrics 1. Colloids or Crystalloids:  have no advantage over Crystalloids  high cost (The SAFE trial and the CRISTAL trial) Crystalloids rapidly equilibrate with the extracellular fluid  only 20% remains in circulation after 1st h. The accepted average ratio of Colloid: Crystalloid is 1:1.5. ABOUBAR ELNASHAR
  • 35. Crystalloid: NS D5NS can be given Ringer Hartmann Ringer=lactated Ringer Nacl: 6.5 g, Kcl:0.42 g, Ca cl: 0.25 g, 1 mol of Na bicarbonate is dissolved in 1 liter of distilled water Colloids: Human albumin, Hydroxyethylstarch (HES) Dextran Mannitol Haemaccel ABOUBAR ELNASHAR Hartmann solution= compound sodium lactate NaCl KCl CaCl dihydrate Na lactate
  • 36. 2. Whole blood or blood component? superior to PRBCs or combined transfusions in preventing acute tubular necrosis and other complications. replaces many coagulation factors its plasma expands blood volume.  exposing the patient to fewer donors. The availability of fresh warm blood in developing countries could provide an alternative to more expensive and infra structure-dependent blood components. ABOUBAR ELNASHAR
  • 37. 3. To cross-match or not to cross-match? The chances of a clinically significant red cell antibody being missed in a patient with a negative antibody screen (false negative) are 1-4/10,000. Given that the chance of adverse consequences is small, in cases of acute massive hge, it appears reasonable to transfuse blood without type-and-screened red blood cells. [Rege et al, 2014] ABOUBAR ELNASHAR
  • 38. 5. Blood Transfusion: How Much& When To Stop?  The decision for blood transfusion  Hb≤6.0 g/dl  almost always required  Hb≥10.0 g/dl  rarely required  Hb is normal but acute hge  Required  Single Hb/ hct  ±misleading  ±:delay initiating red cell transfusion  Serial measurements helpful ABOUBAR ELNASHAR
  • 39.  Goals of management of massive blood loss:  Most protocols recommend maintaining a target  Hct of 21-24%.  Restrictive transfusions and liberal transfusions were of equivalent value in critically ill patients while relatively stable patients undergoing liberal transfusions had a higher 30-day mortality.  [Hébert et al, 2012] Hb ≥8 g/dl Platelet 50x 109/L PT ≤1.5 times normal APPT ≤1.5 times normal Fibrinogen 2g/L ABOUBAR ELNASHAR
  • 40. The risk of dilutional coagulopathy  needs to be borne in mind when multiple units of PRBCs and crystalloids/colloids are used. <10 units of PRBCs rarely need component replacement The lowest mortality occurs in the patients where ratio of plasma and PRBCs is 1:1. Recommend ratio of PRBC, fresh frozen plasma and Platelet of 6: 4:1 in cases of massive hge. ABOUBAR ELNASHAR
  • 41. 6. Management Of Obstetric Haemorrhage With Blood Components There should be a clear local protocol on how to manage major obstetric hge. The protocol should be updated annually and practised in ‘skills drills’ to inform and train relevant personnel. ABOUBAR ELNASHAR
  • 42. 1. Clinicians should familiarise themselves with mechanical strategies that can be employed to reduce postpartum blood loss. rubbing up the fundus bimanual uterine compression emptying the bladder to stimulate uterine contraction ABOUBAR ELNASHAR
  • 43. 2. Blood components used for obstetric hge Red cell transfusion The decision to provide blood transfusion should be made on clinical and haematological grounds.  almost always required when Hb ≤60 g/l  rarely required when the Hb≥100 g/l. Patients with acute hge can have normal Hb: cl evaluation of the patient is extremely important. ABOUBAR ELNASHAR
  • 44. In an extreme situation and when the blood group is unknown: group O RhD-negative red cells should be given (although they may be incompatible for patients with irregular antibodies). Staff working in obstetric units should be aware of the location of the satellite blood fridge (where available) and should ensure that access is possible for blood collection. ABOUBAR ELNASHAR
  • 45. FFP Dose: 12–15 ml/kg for/6 units of red cells during major obstetric hge. Subsequent FFP transfusion should be guided by the results of clotting tests, aiming to maintain PT and APTT ratios at less than 1.5 x normal. During bleeding episodes: Regular full blood counts coagulation screens (PT, APTT and fibrinogen) are performed ABOUBAR ELNASHAR
  • 46. Cryoprecipitate  Dose:  two 5-unit pools should be administered early in major obstetric hge.  Subsequent transfusion should be guided by fibrinogen results  aiming to keep levels above 1.5 g/l. ABOUBAR ELNASHAR
  • 47. Platelets Aim: maintain the platelet count above 50 x 109/l in the acutely bleeding patient. A platelet transfusion trigger of 75 x 109/l is recommended to provide a margin of safety. The platelets should ideally be group compatible. RhD-negative women should also receive RhD- negative platelets. ABOUBAR ELNASHAR
  • 48. SUMMARY Blood transfusion is an essential component of obstetric care and at times lifesaving. Inappropriate transfusions during pregnancy and the postpartum period expose the mother to the risk of HDFN. In the situation of obstetric hge early resuscitation is done with crystalloids with oxygenation while simultaneously taking all steps to control bleeding and reduce the transfusion requirement. A preplanned, multidisciplinary protocol yields the best results in the management. ABOUBAR ELNASHAR
  • 49. The decision to perform a blood transfusion should be made on both clinical and haematological grounds. The majority of protocols recommended that Hct be maintained minimally at 21-24%; however, in actively bleeding patient, target Hct should be 30%. To avoid dilutional coagulopathy,replacement with coagulation factors and platelets may be necessary. Whole blood may be preferred in acute massive hge, especially where blood components are not available. In an extreme situation and when the blood group is unknown, O RhD negative red cells should be given. ABOUBAR ELNASHAR
  • 50. ABOUBAR ELNASHAR You can get this lecture from: 1.My scientific page on Face book: Aboubakr Elnashar Lectures. https://www.facebook.com/groups/2277 44884091351/ 2.Slide share web site 3.elnashar53@hotmail.com 4.My clinic: Elthwara St. Mansura